Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's ...

For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine ...

The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...

The novel oral selective estrogen receptor (ER) degrader giredestrant significantly reduced the risk of invasive disease ...

Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Sara M. Tolaney, ...

The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low ...

Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment between 2015 ...